What happens if I overdose Meropenem Auro Pharma?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include seizures; slow breathing; tremors.
Proper storage of Meropenem Auro Pharma:
Meropenem Auro Pharma is usually handled and stored by a health care provider. If you are using Meropenem Auro Pharma at home, store Meropenem Auro Pharma as directed by your pharmacist or health care provider. Keep Meropenem Auro Pharma out of the reach of children and away from pets.
Overdose of Meropenem Auro Pharma in details
In mice and rats, large intravenous doses of Meropenem Auro Pharma (2200 mg/kg to 4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
Intentional overdosing of Meropenem Auro Pharma I.V. is unlikely, although accidental overdosing might occur if large doses are given to patients with reduced renal function. The largest dose of Meropenem Auro Pharma administered in clinical trials has been 2 grams given intravenously every 8 hours. At this dosage, no adverse pharmacological effects or increased safety risks have been observed.
Limited postmarketing experience indicates that if adverse events occur following overdosage, they are consistent with the adverse event profile described in the Adverse Reactions section and are generally mild in severity and resolve on withdrawal or dose reduction. Consider symptomatic treatments. In individuals with normal renal function, rapid renal elimination takes place. Meropenem Auro Pharma and its metabolite are readily dialyzable and effectively removed by hemodialysis; however, no information is available on the use of hemodialysis to treat overdosage.
What should I avoid while taking Meropenem Auro Pharma?
This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop using Meropenem Auro Pharma and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
Meropenem Auro Pharma warnings
While Meropenem Auro Pharma possesses the characteristic low toxicity of the β-lactam group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.
Prescribing Meropenem Auro Pharma in the absence of a proven or stongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Seizures and other adverse CNS experiences have been reported during treatment with Meropenem Auro Pharma I.V. these experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) or with bacterial meningitis and / or compromised renal function. · Prolong use of Meropenem Auro Pharma may result in overgrowth of nonsusceptible organisms.
Pregnancy:
There are no adequate and well – controlled studies in pregnant women. Therefore Meropenem Auro Pharma should be used during pregnancy only if clearly needed.
Breast feeding:
It is not known whether this drug is excreted in human milk. Caution when Meropenem Auro Pharma is administered to a breast-feeding woman.
What should I discuss with my healthcare provider before taking Meropenem Auro Pharma?
Some medical conditions may interact with Meropenem Auro Pharma. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have had an allergic reaction (eg, rash, hives, itching, difficulty breathing, swelling, dizziness) to a penicillin antibiotic (eg, amoxicillin), a cephalosporin antibiotic (eg, cephalexin), or to any other beta-lactam antibiotic (eg, imipenem)
- if you have kidney or liver problems, bacterial meningitis, or a history of seizures or central nervous system problems (eg, brain lesions), or you are in shock
- if you are on dialysis
Some MEDICINES MAY INTERACT with Meropenem Auro Pharma. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Probenecid because it may increase the actions and the risk of Meropenem Auro Pharma's side effects
- Divalproex sodium or valproic acid because their effectiveness may be decreased by Meropenem Auro Pharma
- Other medicines that may increase your risk of seizures (eg, tramadol) because the risk of seizures may be further increased when combined with Meropenem Auro Pharma. Ask your doctor or pharmacist if you have questions about whether any of your other medicines may increase your risk for seizures
This may not be a complete list of all interactions that may occur. Ask your health care provider if Meropenem Auro Pharma may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Meropenem Auro Pharma precautions
The selection of Meropenem Auro Pharma to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors eg, severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria. As with all β-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported.
Patients who have a history of hypersensitivity to carbapenems, penicillins or other β-lactam antibiotics may also be hypersensitive to Meropenem Auro Pharma. Before initiating therapy with Meropenem Auro Pharma, careful inquiry should be made concerning previous hypersensitivity reactions to β-lactam antibiotics.
If a severe allergic reaction occurs, Meropenem Auro Pharma should be discontinued and appropriate measures taken.
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including Meropenem Auro Pharma, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of Meropenem Auro Pharma. Discontinuation of therapy with Meropenem Auro Pharma and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Seizures have infrequently been reported during treatment with carbapenems, including Meropenem Auro Pharma.
Hepatic functions should be closely monitored during treatment with Meropenem Auro Pharma due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis).
Use in Patients with Liver Disease: Patients with pre-existing liver disorders should have liver function monitored during treatment with Meropenem Auro Pharma. There is no dose adjustment necessary.
A positive direct or indirect Coombs test may develop during treatment with Meropenem Auro Pharma.
The concomitant use of Meropenem Auro Pharma and valproic acid/sodium valproate is not recommended.
Meropenem Auro Pharma injection contains sodium.
Meropenem Auro Pharma contains approximately 2 mEq of sodium per 500-mg dose which should be taken into consideration by patients on a controlled sodium diet.
What happens if I miss a dose of Meropenem Auro Pharma?
Since Meropenem Auro Pharma is usually administered by a healthcare provider, missing a dose is not likely to occur.
References
- DailyMed. "MEROPENEM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "meropenem". http://www.drugbank.ca/drugs/DB00760 (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology